SecBot SecBot
8-K ·Filed Apr 8, 2026

MGNX

MACROGENICS INC
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago SEC0001125345-26-000026
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The lifting of the clinical hold is a positive regulatory development for lorigerlimab, potentially accelerating enrollment and data readout. Monitor for mid-year update on clinical progress.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.44
T+0 close · Apr 8, 2026 · via day close
Latest settled
+32.85%
T+60 · $4.57
Vs SPY
+22.07%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 9 $3.44entry
  2. T+1 · 7mo ago +4.65%α +4.71% · $3.60
  3. T+5 · 7mo ago −0.87%α −4.06% · $3.41
  4. T+20 · 6mo ago −12.50%α −20.07% · $3.01
  5. T+60 · 4mo ago +32.85%α +22.07% · $4.57
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MacroGenics announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study of lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4, for gynecologic cancers. The company plans to resume enrollment and provide a mid-year program update.

Key Facts

  • FDA removed partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab
  • Study evaluates lorigerlimab in patients with platinum-resistant ovarian cancer or clear cell gynecologic cancer
  • To date, 41 patients have been dosed in the LINNET study
  • Company plans to resume enrollment and provide mid-year 2026 update

Financial Impact

Positive for clinical development progress

clinical developmentdrug pipelineregulatory progress

Risk Factors

  • Potential for future safety issues to re-emerge
  • Clinical efficacy may not meet expectations in ongoing trial

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001125345-26-000026
Exhibit: exhibit991_linnetstudyhold.htm0001125345-26-000026
Document: 0001125345-26-000026-index-headers.html0001125345-26-000026
Document: 0001125345-26-000026-index.html0001125345-26-000026
Document: 0001125345-26-000026.txt0001125345-26-000026

Track record

21 reports on MGNX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
  2. Nov 13, 20263d ago 8-K Neutral 4/10 Entry $2.31 Now $2.17 −6.06% settles Feb 12
  3. Nov 12, 20264d ago Press Release Bearish 5/10 Entry $2.20 Now $2.17 +1.36% settles Feb 11
  4. Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  5. Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  6. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  7. Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
  9. Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
  10. Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 8, 2026